The U.S. Food and Drug Administration recently approved aducanumab, the first treatment that aims to slow the progression of Alzheimer’s disease. But approval of the drug has provoked mixed reactions from the scientific community.
Led by a husband-and-wife duo–one a pharmacy professor and the other a chemistry professor–the research team has now set its sights on finding existing drugs to treat COVID-19 and other SARS coronaviruses.